homologous transplantation

Summary

Summary: Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.

Top Publications

  1. ncbi The Banff 97 working classification of renal allograft pathology
    L C Racusen
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Kidney Int 55:713-23. 1999
  2. ncbi Banff 07 classification of renal allograft pathology: updates and future directions
    K Solez
    Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
    Am J Transplant 8:753-60. 2008
  3. ncbi Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo
    Amelia Bartholomew
    University of Illinois, Chicago 60607, USA
    Exp Hematol 30:42-8. 2002
  4. ncbi Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection
    Susan Stewart
    International Society for Heart and Lung Transplantation, Addison, Texas, USA
    J Heart Lung Transplant 24:1710-20. 2005
  5. ncbi Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice
    Nicoletta Eliopoulos
    Lady Davis Institute for Medical Research, McGill University, 3755 Cote St Catherine Rd, Montreal, QC Canada H3T1E2
    Blood 106:4057-65. 2005
  6. ncbi Human mesenchymal stem cells modulate allogeneic immune cell responses
    Sudeepta Aggarwal
    Osiris Therapeutics, 2001 Aliceanna St, Baltimore, MD 21231, USA
    Blood 105:1815-22. 2005
  7. pmc Heterologous immunity provides a potent barrier to transplantation tolerance
    Andrew B Adams
    Emory Transplant Center and Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Clin Invest 111:1887-95. 2003
  8. ncbi Identifying specific causes of kidney allograft loss
    Z M El-Zoghby
    Department of Internal Medicine, Division of Nephrology and Hypertension and William von Liebig Transplant Center, Mayo Clinic, Rochester, MN, USA
    Am J Transplant 9:527-35. 2009
  9. pmc Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9
    Yunchuan Ding
    Transplantation Research Immunology Group, Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Diabetes 58:1797-806. 2009
  10. ncbi Antibodies against MICA antigens and kidney-transplant rejection
    Yizhou Zou
    Transplantation Immunology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8886, USA
    N Engl J Med 357:1293-300. 2007

Detail Information

Publications279 found, 100 shown here

  1. ncbi The Banff 97 working classification of renal allograft pathology
    L C Racusen
    Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Kidney Int 55:713-23. 1999
    ..This manuscript describes a classification, Banff 97, developed by investigators using the Banff Schema and the Collaborative Clinical Trials in Transplantation (CCTT) modification for diagnosis of renal allograft pathology...
  2. ncbi Banff 07 classification of renal allograft pathology: updates and future directions
    K Solez
    Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada
    Am J Transplant 8:753-60. 2008
    ....
  3. ncbi Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo
    Amelia Bartholomew
    University of Illinois, Chicago 60607, USA
    Exp Hematol 30:42-8. 2002
    ..We hypothesized that the activities of MSCs in the bone marrow microenvironment might also include immunomodulatory effects on lymphocytes...
  4. ncbi Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection
    Susan Stewart
    International Society for Heart and Lung Transplantation, Addison, Texas, USA
    J Heart Lung Transplant 24:1710-20. 2005
    ..Technical considerations in biopsy processing are also addressed. This consensus revision of the Working Formulation was approved by the ISHLT Board of Directors in December 2004...
  5. ncbi Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice
    Nicoletta Eliopoulos
    Lady Davis Institute for Medical Research, McGill University, 3755 Cote St Catherine Rd, Montreal, QC Canada H3T1E2
    Blood 106:4057-65. 2005
    ..These results strongly suggest that MSCs are not intrinsically immunoprivileged and cannot serve as a "universal donor" in immunocompetent MHC-mismatched recipients...
  6. ncbi Human mesenchymal stem cells modulate allogeneic immune cell responses
    Sudeepta Aggarwal
    Osiris Therapeutics, 2001 Aliceanna St, Baltimore, MD 21231, USA
    Blood 105:1815-22. 2005
    ....
  7. pmc Heterologous immunity provides a potent barrier to transplantation tolerance
    Andrew B Adams
    Emory Transplant Center and Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Clin Invest 111:1887-95. 2003
    ..These data offer a potential explanation for the difficulty encountered when inducing tolerance in nonhuman primates and human patients and provide insight into the signaling pathways essential for memory T cell activation and function...
  8. ncbi Identifying specific causes of kidney allograft loss
    Z M El-Zoghby
    Department of Internal Medicine, Division of Nephrology and Hypertension and William von Liebig Transplant Center, Mayo Clinic, Rochester, MN, USA
    Am J Transplant 9:527-35. 2009
    ..This study identifies targets for investigation and intervention that may result in improved kidney transplantation outcomes...
  9. pmc Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9
    Yunchuan Ding
    Transplantation Research Immunology Group, Nuffield Department of Surgery, University of Oxford, John Radcliffe Hospital, Oxford, UK
    Diabetes 58:1797-806. 2009
    ..Mesenchymal stem cells (MSCs) are known to be capable of suppressing immune responses, but the molecular mechanisms involved and the therapeutic potential of MSCs remain to be clarified...
  10. ncbi Antibodies against MICA antigens and kidney-transplant rejection
    Yizhou Zou
    Transplantation Immunology Division, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390 8886, USA
    N Engl J Med 357:1293-300. 2007
    ..We sought to determine whether an immune response to MICA antigens might play a role in the failure of kidney allografts...
  11. ncbi Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy
    M R Mehra
    University of Maryland School of Medicine, Baltimore, Maryland, USA
    Am J Transplant 6:1248-56. 2006
    ..As the use of new assessment tools increases our understanding of this disease, better preventative and treatment strategies are evolving...
  12. ncbi Outcomes and DNA analysis of ex vivo expanded stem cell allograft for ocular surface reconstruction
    Sheraz M Daya
    Corneo Plastic Unit, Queen Victoria Hospital, East Grinstead, West Sussex, United Kingdom
    Ophthalmology 112:470-7. 2005
    ..To investigate the outcome of a new technique of ex vivo expanded stem cell allograft for limbal stem cell deficiency (LSCD), and to characterize the ocular surface genotype after surgery...
  13. ncbi Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies?
    Herwig Ulf Meier-Kriesche
    Department of Medicine, University of Florida, Gainesville, FL, USA
    Am J Transplant 4:1289-95. 2004
    ..Redirection of attention from early endpoints towards the process of long-term graft loss may be necessary to sustain early gains in the long term...
  14. ncbi B lymphocyte-directed immunotherapy promotes long-term islet allograft survival in nonhuman primates
    Chengyang Liu
    Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA
    Nat Med 13:1295-8. 2007
    ..Development of donor-specific alloantibodies was abrogated only in the setting of continued rapamycin monotherapy...
  15. pmc Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance
    Sophie Brouard
    Institut National de la Sante et de la Recherche Medicale, U643, Centre Hospitalier Universitaire de Nantes, Institut de Transplantation et de Recherche en Transplantation, and Université de Nantes, Faculte de Medicine, F 44000 Nantes, France
    Proc Natl Acad Sci U S A 104:15448-53. 2007
    ..Further validation of this tool for safe IS minimization in prospective clinical trials is warranted...
  16. ncbi Pretransplant infusion of mesenchymal stem cells prolongs the survival of a semiallogeneic heart transplant through the generation of regulatory T cells
    Federica Casiraghi
    Transplant Research Center, Chiara Cucchi De Alessandri and Gilberto Crespi, Ranica, Italy
    J Immunol 181:3933-46. 2008
    ....
  17. ncbi Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults
    Rosa Gonzalo-Daganzo
    Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, Madrid, Spain
    Cytotherapy 11:278-88. 2009
    ..Our objectives were to evaluate co-infusion of mesenchymal stromal cells (MSC) from the same TPD regarding tolerance, CB engraftment and effects on acute (a)GvHD, both preventive and therapeutic...
  18. ncbi Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study
    R E Curtis
    Division of Cancer Epidemiology, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA
    Blood 94:2208-16. 1999
    ..0% +/- 2.9% and 22% +/- 17.9%, respectively. We conclude that factors associated with altered immunity and T-cell regulatory mechanisms are predictors of both early- and late-onset PTLD...
  19. ncbi Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection
    Thomas Fehr
    Division of Nephrology, University Hospital, Zurich, Switzerland
    Transplantation 87:1837-41. 2009
    ..Thus, rituximab/IVIG may be a useful strategy for the treatment of chronic AMR, but further randomized multicenter studies are necessary to establish its efficacy and safety profile...
  20. ncbi Abrogation of anti-HLA antibodies via proteasome inhibition
    Hargovind L Trivedi
    Department of Nephrology and Transplantation Medicine, Institute of Kidney Diseases and Research Centre Institute of Transplantation Sciences, Ahmedabad, Gujarat, India
    Transplantation 87:1555-61. 2009
    ..We report the first clinical experience with a plasma cell depleting therapy, bortezomib, to abrogate anti-HLA antibodies in transplantation (outside of rejection) in an attempt to improve long-term allograft survival...
  21. ncbi Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats
    Yukiko Imanishi
    Division of Cardiovascular Surgery, Department of Surgery, Graduate School of Medicine, Osaka University, Japan
    J Mol Cell Cardiol 44:662-71. 2008
    ..We conclude that allogenic MSC transplantation therapy is useful for AMI. The donor MSCs disappear rapidly, but become a trigger of VEGF paracrine effect, without induction of immune rejection...
  22. ncbi CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation
    Matthias Edinger
    Division of Bone Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, 300 Pasteur Drive, Stanford, California 94305, USA
    Nat Med 9:1144-50. 2003
    ..Thus, CD4+CD25+ T cells are potent regulatory cells that can separate GVHD from GVT activity mediated by conventional donor T cells...
  23. ncbi Studying the immunosuppressive role of indoleamine 2,3-dioxygenase: tryptophan metabolites suppress rat allogeneic T-cell responses in vitro and in vivo
    Thomas M Bauer
    Department of Transplantation Immunology, Institute of Immunology, University of Heidelberg, 69120 Heidelberg, Germany
    Transpl Int 18:95-100. 2005
    ..The metabolites induced a significant prolongation (P = 0.0018) of graft survival. We conclude that IDO-induced tryptophan metabolites suppress the T-cell response and prolong allograft survival in rats...
  24. ncbi Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis
    Yaojiong Wu
    161 HMRC, University of Alberta, 113 Street and 87 Avenue, Edmonton, Alberta T6G 2E1, Canada
    Stem Cells 25:2648-59. 2007
    ..Thus, our data suggest that BM-MSCs promote wound healing through differentiation and release of proangiogenic factors. Disclosure of potential conflicts of interest is found at the end of this article...
  25. ncbi Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells
    Katarina Le Blanc
    Division of Clinical Immunology and Centre for Allogeneic Stem Cell Transplantation, Karolinska Institutet, Huddinge University Hospital, Stockholm, Sweden
    Lancet 363:1439-41. 2004
    ..Clinical response was striking. The patient is now well after 1 year. We postulate that mesenchymal stem cells have a potent immunosuppressive effect in vivo...
  26. ncbi Ex vivo expansion and prophylactic infusion of CMV-pp65 peptide-specific cytotoxic T-lymphocytes following allogeneic hematopoietic stem cell transplantation
    Kenneth Micklethwaite
    Westmead Millennium Institute, University of Sydney at Westmead Hospital, Sydney, Australia
    Biol Blood Marrow Transplant 13:707-14. 2007
    ..Prophylactic adoptive transfer of NLV-specific T cells is safe and may be effective in preventing cytomegalovirus reactivation...
  27. ncbi Pretransplant cellular alloimmunity as assessed by a panel of reactive T cells assay correlates with acute renal graft rejection
    Emilio D Poggio
    Department of Nephrology and Hypertension, Transplant Center, Cleveland Clinic, Cleveland, OH 44195, USA
    Transplantation 83:847-52. 2007
    ....
  28. ncbi Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity
    Michael Boeckh
    Program in Infectious Diseases Immunology, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Blood 101:407-14. 2003
    ..Prevention strategies should be targeted at patients in whom CMV reactivated during the first 3 months and those with poor CMV-specific immunity or low CD4 counts...
  29. pmc Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts
    H Nagano
    Department of Surgery, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 100:550-7. 1997
    ..Thus, development of GAD, but not parenchymal rejection, requires IFN-gamma. Reduced expression of MHC antigens and leukocyte adhesion molecules may contribute to the lack of coronary arteriopathy in hearts allografted into GKO mice...
  30. ncbi Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  31. pmc CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus-host disease
    José L Cohen
    Laboratoire de Biologie et Thérapeutique des Pathologies Immunitaires, Centre National de la Recherche Scientifique UMR 7087, Hopital Pitie Salpetriere, 756651 Paris, France
    J Exp Med 196:401-6. 2002
    ..Thus, CD4(+)CD25(+) regulatory T cells represent a new therapeutic tool for controlling GVHD in allogeneic HSCT. More generally, these results outline the tremendous potential of regulatory T cells as therapeutics...
  32. pmc Human allograft acceptance is associated with immune regulation
    A M VanBuskirk
    Department of Surgery, Ohio State University, Columbus, Ohio, USA
    J Clin Invest 106:145-55. 2000
    ..This demonstrates that allograft acceptance in humans is associated with an immune regulation pattern, which may be useful in the diagnosis and/or monitoring of transplant patients for allograft acceptance...
  33. ncbi Chemokines and their receptors in allograft rejection
    W W Hancock
    Millennium Pharmaceuticals Incorparated, Cambridge, MA 02139, USA
    Curr Opin Immunol 12:511-6. 2000
    ..Recent literature has demonstrated the presence of chemokines and their receptors in transplants and some studies demonstrate important functional roles...
  34. ncbi Monitoring of cytomegalovirus reactivation after allogeneic stem cell transplantation: comparison of an antigenemia assay and quantitative real-time polymerase chain reaction
    K Yakushiji
    Second Department of Internal Medicine, Kurume University School of Medicine, Kurume, Japan
    Bone Marrow Transplant 29:599-606. 2002
    ..Although PCR is more sensitive than antigenemia, both tests are useful in the early detection of CMV after allogeneic stem cell transplantation...
  35. ncbi Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus
    Viorica Bumbea
    Multiorgan Transplant Unit, University Hospital, Toulouse, France
    Nephrol Dial Transplant 20:2517-23. 2005
    ..Switching from calcineurin inhibitors (CNIs) to sirolimus might improve renal function in chronic renal transplant patients...
  36. ncbi Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation
    S Ganepola
    Department of Internal Medicine III, Charite, Campus Benjamin Franklin, Hindenburgdamm, Berlin, Germany
    Bone Marrow Transplant 39:293-9. 2007
    ..We recommend preferring CMV seropositive donors for CMV seropositive recipients, as this should lead to durable CMV-specific T-cell responses soon after transplantation with consecutive protection from CMV disease...
  37. ncbi Costimulation blockade with belatacept in renal transplantation
    Flavio Vincenti
    University of California, San Francisco, San Francisco, USA
    N Engl J Med 353:770-81. 2005
    ..The use of potentially less toxic agents, such as belatacept, a selective blocker of T-cell activation, may improve outcomes...
  38. ncbi Long-term islet allograft survival in nonobese diabetic mice treated with tacrolimus, rapamycin, and anti-interleukin-2 antibody
    R Damaris Molano
    Cell Transplant Center, Diabetes Research Institute, Miami, FL 33136, USA
    Transplantation 75:1812-9. 2003
    ....
  39. ncbi Neuroendocrine profiling of humans receiving cardiac allografts
    Tsuneo Ogawa
    Cardiovascular Endocrinology Laboratory, University of Ottawa Heart Institute, Ontario, Canada
    J Heart Lung Transplant 24:1046-54. 2005
    ..As a result, plasma levels of various hormones and autocoids have been associated with cardiac allograft rejection status. However, no clear associations can be defined given the highly contradictory nature of the available literature...
  40. pmc Late kidney allograft loss: what we know about it, and what we can do about it
    Anthony M Jevnikar
    Department of Medicine, Lawson Health Research Institute and Robarts Research Institute, London Health Sciences Centre, University of Western Ontario, London, Ontario, Canada
    Clin J Am Soc Nephrol 3:S56-67. 2008
    ..Understanding the basic pathogenesis sufficiently to allow early intervention may finally benefit patients who are at high risk for tubular atrophy and interstitial fibrosis and promote their long-term graft function...
  41. pmc Mixed chimerism
    M Sykes
    Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02129, USA
    Philos Trans R Soc Lond B Biol Sci 356:707-26. 2001
    ....
  42. ncbi Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss
    M J Everly
    Department of Surgery, Transplantation Division, University of Cincinnati College of Medicine, Cincinnati, OH, USA
    Am J Transplant 9:1063-71. 2009
    ..039). De novo DSAs detected at rejection are associated with reduced allograft survival, but prompt DSA reduction was associated with improved allograft survival. DSA should be considered a potential new end point for rejection therapy...
  43. ncbi Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age
    C Kollman
    National Marrow Donor Program, Research Department, Minneapolis, MN 55413, USA
    Blood 98:2043-51. 2001
    ..0001). The use of younger donors may lower the incidence of GVHD and improve survival after bone marrow transplantation. Age should be considered when selecting among comparably HLA-matched volunteer donors...
  44. ncbi The immune response to corneal allograft requires a site-specific draining lymph node
    Jarmila Plsková
    Department of Ophthalmology, University of Aberdeen, Medical School Foresterhill, Aberdeen, AB25 2ZD, Scotland, UK
    Transplantation 73:210-5. 2002
    ..In this study we have investigated further the role of the DLN and spleen in corneal graft rejection in mice...
  45. ncbi Mesenchymal stem cells and their potential as cardiac therapeutics
    Mark F Pittenger
    Osiris Therapeutics, Inc, 2001 Aliceanna St, Baltimore, MD 21231, USA
    Circ Res 95:9-20. 2004
    ....
  46. ncbi The role of autoimmunity in islet allograft destruction: major histocompatibility complex class II matching is necessary for autoimmune destruction of allogeneic islet transplants after T-cell costimulatory blockade
    Leila Makhlouf
    Laboratory of Immunogenetics and Transplantation, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Diabetes 51:3202-10. 2002
    ..Our results may have implications for the design of future clinical trials in islet transplantation...
  47. ncbi Local production and activation of complement up-regulates the allostimulatory function of dendritic cells through C3a-C3aR interaction
    Qi Peng
    Medical Research Council Centre for Transplantation, Department of Nephrology and Transplantation, King s College London, London, United Kingdom
    Blood 111:2452-61. 2008
    ..This mechanism, in addition to underpinning the cell-autonomous action of donor C3 on allostimulation, has implications for a wider range of immune responses in self-restricted T-cell priming...
  48. pmc Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting
    Alma J Nauta
    Laboratory of Experimental Hematology, Department of Hematology, D2 P, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands
    Blood 108:2114-20. 2006
    ....
  49. ncbi High active local levels of vancomycin without nephrotoxicity released from impacted bone allografts in 20 revision hip arthroplasties
    Martin A Buttaro
    Hip Surgery Unit, Carlos E Ottolenghi Institute of Orthopaedics, Hospital Italiano de Buenos Aires
    Acta Orthop 76:336-40. 2005
    ..However, local and systemic antibiotic levels, biological activity of vancomycin, interaction with antibiotic-loaded cement, and also nephrotoxicity of these composites have not yet been studied clinically...
  50. pmc Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection
    W Gao
    LeukoSite Inc, Cambridge, Massachusetts 02142, USA
    J Clin Invest 105:35-44. 2000
    ..We conclude that therapies to block CCR1/ligand interactions may prove useful in preventing acute and chronic rejection clinically...
  51. ncbi Dendritic cell synthesis of C3 is required for full T cell activation and development of a Th1 phenotype
    Qi Peng
    Department of Nephrology and Transplantation, King s College London School of Medicine at Guy s, King s College and St Thomas Hospitals, London SE1 9RT, United Kingdom
    J Immunol 176:3330-41. 2006
    ....
  52. pmc NK cells promote transplant tolerance by killing donor antigen-presenting cells
    Guang Yu
    Transplant Research Center, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
    J Exp Med 203:1851-8. 2006
    ..Our study identified a novel role for NK cells in regulating T cell priming in transplant models, and may have important clinical implications in tolerance induction...
  53. pmc Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients
    Francesco Dotta
    Department of Internal Medicine, Endocrine and Metabolic Sciences, and Biochemistry, University of Siena, 53100 Siena, Italy
    Proc Natl Acad Sci U S A 104:5115-20. 2007
    ..These studies provide direct evidence that enterovirus can infect beta cells in patients with type 1 diabetes and that infection is associated with inflammation and functional impairment...
  54. ncbi Expression of the chemokine antagonist vMIP II using a non-viral vector can prolong corneal allograft survival
    Radhakrishna G Pillai
    Department of Immunology, Division of Medicine, Imperial College London, Hammersmith Campus, London, UK
    Transplantation 85:1640-7. 2008
    ....
  55. ncbi Impact of rituximab therapy for treatment of acute humoral rejection
    Z Kaposztas
    Department of Surgery, The University of Texas Medical School at Houston, Houston, Texas, USA
    Clin Transplant 23:63-73. 2009
    ..This retrospective analysis documented the benefit of rituximab administration in addition to plasmapheresis (PP)...
  56. ncbi Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation
    R Childs
    Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1652, USA
    N Engl J Med 343:750-8. 2000
    ....
  57. ncbi Prospective and challenges of islet transplantation for the therapy of autoimmune diabetes
    A N Balamurugan
    Thomas E Starzl Transplantation Institute, Department of Surgery, University of Pittsburgh, Pittsburgh, PA 15261, USA
    Pancreas 32:231-43. 2006
    ..All together, islet cell transplantation is moving forward...
  58. pmc Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone
    Edwin M Horwitz
    Transplantation and Gene Therapy Program, St Jude Children s Research Hospital, 332 North Lauderdale, Memphis, TN 38105, USA
    Proc Natl Acad Sci U S A 99:8932-7. 2002
    ..Thus, allogeneic mesenchymal cells offer feasible posttransplantation therapy for osteogenesis imperfecta and likely other disorders originating in mesenchymal precursors...
  59. ncbi Mesenchymal stromal cells lose their immunosuppressive potential after allotransplantation
    Tatyana B Prigozhina
    Department of Bone Marrow Transplantation, Hadassah University Hospital, Jerusalem, Israel
    Exp Hematol 36:1370-6. 2008
    ..In this study we examined whether MSCs retain their immunomodulating properties in vivo after allotransplantation...
  60. ncbi Immune reconstitution to cytomegalovirus after allogeneic hematopoietic stem cell transplantation: impact of host factors, drug therapy, and subclinical reactivation
    Morgan Hakki
    Fred Hutchinson Cancer Research Center, and the University of Washington, Seattle, USA
    Blood 102:3060-7. 2003
    ..Subclinical CMV reactivation while on ganciclovir appears to be a potent stimulator of T-cell function. These findings have implications for vaccination and adoptive-immunotherapy strategies in this population...
  61. ncbi Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial
    Stanley C Jordan
    Renal Transplant Program, Cedars Sinai Medical Center, UCLA School of Medicine, 8635 W 3rd Street, Suite 590W, Los Angeles, CA 90048, USA
    J Am Soc Nephrol 15:3256-62. 2004
    ..Transplant rates for highly sensitized patients with ESRD awaiting kidney transplants are improved with IVIG therapy...
  62. ncbi Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis
    Andrea Augello
    Department of Oncology, Biology, and Genetics, University of Genoa, National Institute for Cancer Research, Genoa, Italy
    Arthritis Rheum 56:1175-86. 2007
    ..We explored the feasibility of using allogeneic MSCs as therapy for collagen-induced arthritis, a mouse model for human rheumatoid arthritis...
  63. pmc Allogeneic endometrial regenerative cells: an "Off the shelf solution" for critical limb ischemia?
    Michael P Murphy
    Division of Vascular Surgery, Indiana University School of Medicine, Indiana, USA
    J Transl Med 6:45. 2008
    ....
  64. ncbi Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma
    H de Lavallade
    Unité de Transplantation et de Thérapie Cellulaire UTTC, Institut Paoli Calmettes, Marseille, France
    Bone Marrow Transplant 41:953-60. 2008
    ..35; 95% CI, 0.15-0.82; P=0.01). These data suggest a potential benefit for RIC allo-SCT in the management of relapsed MM warranting further prospective investigations...
  65. pmc Levels of Foxp3 in regulatory T cells reflect their functional status in transplantation
    Sunil K Chauhan
    Schepens Eye Research Institute, Boston, MA 02114, USA
    J Immunol 182:148-53. 2009
    ..These findings provide new insights on Treg dynamics in transplantation, which are crucial for designing therapeutic strategies to modulate Treg function and to optimize Treg-based cell therapies for clinical translation...
  66. ncbi Outcome of diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients
    Bekele Afessa
    Department of Medicine, Divisions of Pulmonary and Critical Care Medicine and Hematology, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
    Am J Respir Crit Care Med 166:1364-8. 2002
    ..This study shows that survival rate of hematopoietic stem cell transplant recipients with diffuse alveolar hemorrhage is better than previously reported, and that early onset and autologous transplant are favorable prognostic indicators...
  67. ncbi A biomechanical comparison of three lower extremity tendons for ligamentous reconstruction about the knee
    Albert W Pearsall
    Department of Orthopaedic Surgery, Section of Sports Medicine and Orthopaedic Biomechanics Laboratory, University of South Alabama Medical Center, Mobile, Alabama, USA
    Arthroscopy 19:1091-6. 2003
    ..The purpose of this investigation was to evaluate 3 previously unreported allograft tendons for use in knee surgery. These are the doubled tibialis anterior (TA), doubled tibialis posterior (TP), and doubled peroneus longus (PL) tendons...
  68. ncbi Autologous and homologous transplantation of bovine spermatogonial stem cells
    F Izadyar
    Department of Endocrinology, Faculty of Biology, Utrecht University, Utrecht, The Netherlands
    Reproduction 126:765-74. 2003
    ..of the calves were hemicastrated to allow autologous transplantation and the other half were used for homologous transplantation. Approximately 20 g of each testis was used for cell isolation...
  69. ncbi Recipient memory-like lymphocytes remain unresponsive to graft antigens after CAMPATH-1H induction with reduced maintenance immunosuppression
    Piotr Trzonkowski
    Transplantation Research Immunology Group and Oxford Transplant Centre, Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom
    Transplantation 82:1342-51. 2006
    ..Treatment with CAMPATH-1H at the time of transplantation allows reduced maintenance immunosuppression. We hypothesized that CAMPATH-1H induction would modulate the response of repopulating leukocytes to donor alloantigens...
  70. ncbi Cortical allograft as a vehicle for antibiotic delivery
    Eivind Witsø
    Department of Orthopaedic Surgery, Norwegian University of Science and Technology, Trondheim
    Acta Orthop 76:481-6. 2005
    ..Infection can be a devastating complication after implantation of a cortical bone allograft. The allograft could act as a vehicle for local antibiotic prophylaxis...
  71. ncbi Immunotherapy of multiple myeloma: the start of a long and tortuous journey
    Simon J Harrison
    DHMO, Peter MacCallum Cancer Centre and Locked Bag 1, A becket Street, Melbourne, Victoria 8006, Australia
    Expert Rev Anticancer Ther 6:1769-85. 2006
    ....
  72. ncbi Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
    N T Ueno
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:986-93. 1998
    ..To evaluate the feasibility of allogeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer...
  73. ncbi Identification of gene markers for the prediction of allograft rejection or permanent acceptance
    B Sawitzki
    Institute of Medical Immunology, Charité University Medicine Berlin Campus Mitte, Germany
    Am J Transplant 7:1091-102. 2007
    ..Interestingly, downregulation of TOAG-1 and alpha-1,2-mannosidase expression occurred in graft infiltrating cells and expression of both genes was also downregulated after T-cell activation in vitro...
  74. ncbi Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)
    O N Koc
    Division of Hematology Oncology, Department of Medicine at Case Western Reserve University and University Hospitals of Cleveland, Cleveland, OH 44106, USA
    Bone Marrow Transplant 30:215-22. 2002
    ..We conclude that donor allogeneic MSC infusion is safe and may be associated with reversal of disease pathophysiology in some tissues. The role of MSCs in the management of Hurler syndrome and MLD should be further evaluated...
  75. pmc Cardiac repair with intramyocardial injection of allogeneic mesenchymal stem cells after myocardial infarction
    Luciano C Amado
    Department of Medicine, Cardiology Division, The Johns Hopkins Hospital, Blalock 618, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Proc Natl Acad Sci U S A 102:11474-9. 2005
    ....
  76. pmc Proinflammatory functions of vascular endothelial growth factor in alloimmunity
    Marlies E J Reinders
    Division of Nephrology, Department of Medicine, Children s Hospital, 300 Longwood Avenue, Boston, Massachusetts 02115, USA
    J Clin Invest 112:1655-65. 2003
    ..Thus, VEGF appears to be functional in acute allograft rejection via its effects on leukocyte trafficking. Together, these observations provide mechanistic insight into the proinflammatory function of VEGF in immunity...
  77. ncbi Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models
    Liying Liu
    John P Robarts Research Institute, London, ON, Canada
    Transplantation 77:1652-60. 2004
    ..We have assessed the effects of three viral chemokine-binding proteins with differing ranges of chemokine inhibition on plaque growth in rats after aortic allograft transplant...
  78. ncbi Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice
    Gudrun E Koehl
    Department of Surgery, The University of Regensburg, Regensburg, Germany
    Transplantation 77:1319-26. 2004
    ..Notably, CsA protects allografts from rejection, but cancer progression is promoted in transplant recipients...
  79. pmc Tolerance: of mice and men
    David H Sachs
    Transplantation Biology Research Center, Massachusetts General Hospital, Boston, Massachusetts 02129, USA
    J Clin Invest 111:1819-21. 2003
    ..An important study now reveals that individuals harboring virally-induced memory T cells that are cross reactive with donor alloantigen are resistant to conventional strategies designed to induce transplant tolerance...
  80. ncbi Impact on the cytomegalovirus (CMV) viral load by CMV-specific T-cell immunity in recipients of allogeneic stem cell transplantation
    G Avetisyan
    Department of Medicine, Division of Haematology, Karolinska Institutet, Karolinska University Hospital in Huddinge, Stockholm 14186, Sweden
    Bone Marrow Transplant 38:687-92. 2006
    ..Recovery of CMV-specific immunity might be delayed in patients with CMV disease. These observations suggest that detection of CMV-specific T-cells is useful in assessing the immunity against CMV...
  81. pmc Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes
    Olivier Joffre
    Institut National de la Sante et de la Recherche Medicale, U563, Tolerance and Autoimmunity section, Toulouse, F 31300 France
    Nat Med 14:88-92. 2008
    ..Our findings demonstrate the potential of appropriately stimulated regulatory T cells for future cell-based therapeutic approaches to induce lifelong immunological tolerance to allogeneic transplants...
  82. pmc A biomarker panel for acute graft-versus-host disease
    Sophie Paczesny
    Department of Pediatrics, University of Michigan, Ann Arbor, USA
    Blood 113:273-8. 2009
    ..A panel of 4 biomarkers can confirm the diagnosis of GVHD in patients at onset of clinical symptoms of GVHD and provide prognostic information independent of GVHD severity...
  83. ncbi Tolerizing effects of co-stimulation blockade rest on functional dominance of CD4+CD25+ regulatory T cells
    Jeroen J A Coenen
    Department of Bloodtransfusion and Transplantation Immunology ABTI OV603, University Medical Center Nijmegen, 6500 HB Nijmegen, The Netherlands
    Transplantation 79:147-56. 2005
    ..This induced suppressive capacity was found to be dependent on the presence of CD4CD25 T cells at the start of MLR...
  84. ncbi A survey of diagnosis, management, and grading of chronic GVHD
    Stephanie J Lee
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Biol Blood Marrow Transplant 8:32-9. 2002
    ..We conclude that studies defining appropriate diagnostic pathways, criteria for disease activity, and prognosis could help standardize management of cGVHD. There is an urgent need to develop and test new approaches to treat cGVHD...
  85. ncbi Radiological and histological analysis of cortical allografts: an experimental study in sheep femora
    Hirofumi Taira
    Department of Orthopaedic Surgery, Oita Medical University, Oita, Japan
    Arch Orthop Trauma Surg 124:320-5. 2004
    ..We developed an experimental model in sheep femora to evaluate the process of cortical allograft incorporation...
  86. ncbi Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation
    Jan Storek
    Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
    Transplantation 73:1154-8. 2002
    ..without irradiation), acute graft-versus-host disease (aGVHD), or chronic graft-versus-host disease (cGVHD) in multivariate analysis. We conclude that patient age is the primary determinant of CD4 T-lymphopoiesis after allogeneic HCT...
  87. ncbi Rat CD8+ FOXP3+ T suppressor cells mediate tolerance to allogeneic heart transplants, inducing PIR-B in APC and rendering the graft invulnerable to rejection
    Jiawang Liu
    Columbia University, Department of Pathology, 630 West 168th Street P and S 14 401, New York, NY 10032, USA
    Transpl Immunol 13:239-47. 2004
    ..This study focuses attention on the need to develop agents that act directly on graft EC in order to achieve tolerance...
  88. ncbi Attenuated acute cardiac rejection in NOS2 -/- recipients correlates with reduced apoptosis
    J Koglin
    Cardiovascular Biology Laboratory, Harvard School of Public Health, Boston, Mass 02115, USA
    Circulation 99:836-42. 1999
    ..To determine whether apoptosis promoted by NOS2 may contribute, we used a heterotopic transplant model to study mouse cardiac allografts placed in recipients with targeted gene deletion of NOS2...
  89. ncbi Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein
    N Utku
    Institut fur Medizinische Immunologie, Campus Mitte, Humboldt Universitat zu Berlin, Germany
    Immunity 9:509-18. 1998
    ..Targeting of TIRC7 may provide a novel therapeutic approach for modulation of the immune response...
  90. ncbi Knowledge about transplantation tolerance gained in primates
    S J Knechtle
    Department of Surgery, University of Wisconsin Hospital, Madison 53792 7375, USA
    Curr Opin Immunol 12:552-6. 2000
    ..Interactive work in these three areas has yielded much new information on mechanisms of tolerance and opened the door to pilot clinical trials. Clinical application of xenotransplantation is likely to depend on such strategies...
  91. ncbi Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients
    Giovanni Stallone
    Department of Biomedical Sciences, Division of Nephrology, University of Foggia, Foggia, Italy
    J Am Soc Nephrol 16:3755-62. 2005
    ..005). This study demonstrates that rapamycin introduction/CNI withdrawal improves graft survival and reduces interstitial and vascular alpha-SMA expression, slowing down the progression of allograft injury in patients with CAN...
  92. ncbi NK cells mediate costimulation blockade-resistant rejection of allogeneic stem cells during nonmyeloablative transplantation
    L S Kean
    Emory Transplant Center, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia, USA
    Am J Transplant 6:292-304. 2006
    ....
  93. ncbi Allograft transplantation in the knee: tissue regulation, procurement, processing, and sterilization
    C Thomas Vangsness
    Department of Orthopaedic Surgery, Keck School of Medicine at the University of Southern California, Los Angeles, California 90033 4608, USA
    Am J Sports Med 31:474-81. 2003
    ..Orthopaedic surgeons who use allograft tissue must understand the tissue banking process to provide safe and effective tissues to their patients...
  94. ncbi The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study
    H Ning
    Department of Hematopoietic Stem Cell Transplantation, Affiliated Hospital to Academy of Military Medical Sciences, Beijing, People s Republic of China
    Leukemia 22:593-9. 2008
    ..We conclude that use of MSCs must be handled with extreme caution before a large-scale clinical trial is performed...
  95. ncbi Human allograft arterial injury is ameliorated by sirolimus and cyclosporine and correlates with suppression of interferon-gamma
    Tai Yi
    Department of Surgery, Section of Organ Transplantation and Immunology, Yale University School of Medicine, New Haven, CT 06510, USA
    Transplantation 81:559-66. 2006
    ..This study evaluated whether sirolimus (SRL), with cyclosporine A (CsA) or alone, affects TA, and examined possible mechanisms of action...
  96. ncbi Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disorder simultaneously affecting both B and T cells after allogeneic bone marrow transplantation
    Tatsuya Chuhjo
    Cellular Transplantation Biology, Kanazawa University Graduate School of Medical Science, Japan
    Am J Hematol 72:255-8. 2003
    ..This case clearly indicates that EBV can simultaneously infect B and T cells and can induce clonal proliferation of both lymphocyte subsets in severely immunocompromised patients...
  97. ncbi Regulation of the epithelial cell-specific integrin, CD103, by human CD8+ cytolytic T lymphocytes
    G A Hadley
    Department of Surgery, University of Maryland Medical School, Baltimore 21201, USA
    Transplantation 67:1418-25. 1999
    ..The goal of the present study was to assess the relevance of these data to the human system...
  98. ncbi Successful renovascular reconstruction for renal allografts with multiple renal arteries
    Kazuhide Makiyama
    Department of Urology, Tokyo Women s Medical University, Tokyo, Japan
    Transplantation 75:828-32. 2003
    ..In the present study, we retrospectively reviewed multiple renal artery reconstruction in kidney transplantation to elucidate the usefulness of these grafts...
  99. ncbi B-type natriuretic peptide as a marker of allograft rejection after heart transplantation
    Angelika Hammerer-Lercher
    Department of Medical Chemistry and Biochemistry, Division of Clinical Biochemistry, Innsbruck Medical University, Innsbruck, Austria
    J Heart Lung Transplant 24:1444. 2005
    ..BNP monitoring seems to be a useful addition in the individual follow-up of heart transplant recipients to rule out significant rejection...
  100. ncbi Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients
    David San Segundo
    Servicios Inmunología, Hospital Universitario Marques de Valdecilla, Santander, Spain
    Transplantation 82:550-7. 2006
    ..Recently, increased frequencies of CD4CD25 regulatory T cells (Tregs) have been described as an additional mechanism that induces alloimmune tolerance...
  101. ncbi Allograft versus autograft patellar tendon anterior cruciate ligament reconstruction: A 5-year follow-up
    R K Peterson
    Davis Orthopaedics and Sports Medicine, Davis, California, USA
    Arthroscopy 17:9-13. 2001
    ..A trend toward greater loss of extension in autografts (2.47 degrees ) than allografts (1.07 degrees ) was seen at 5-year follow-up, not seen at 2 years...

Research Grants63

  1. GLOBIN GENE TRANSFER FOR THERAPY OF SICKLE CELL ANEMIA
    Michel Sadelain; Fiscal Year: 2004
    ....
  2. Neonatal Chemoselection Following Ex Vivo Gene Transfer For Hereditary Disorders
    KARIN L GAENSLER; Fiscal Year: 2012
    ..abstract_text> ..
  3. Novel Strategies to Increase Insulin Independence after Islet Autotransplantation
    Hongjun Wang; Fiscal Year: 2013
    ..abstract_text> ..
  4. Processing and Preservation of Human Umbilical Cord Stem Cells for Cell Therapeut
    Alfred Bahnson; Fiscal Year: 2010
    ..This project will study how to maximize the stocks of these cells and ensure their safe use in cell therapy. ..
  5. Lentivirus-based positive/negative selection in minimally ablative transplants
    KARIN L GAENSLER; Fiscal Year: 2013
    ....
  6. Islet and Mesenchymal Stem Cell Co-transplantation Prevents Onset of Diabetes
    Hongjun Wang; Fiscal Year: 2013
    ..Based on our active islet transplantation program at MUSC, this treatment procedure can be readily translated into therapy to benefit patient care. ..
  7. Role of the thymic epithelium on the outcome of allogeneic transplantation
    Konstantina Alexandropoulos; Fiscal Year: 2013
    ....
  8. Allogeneic Placental Stem Cells for Tissue Repair and Regeneration
    Vijay Kumar; Fiscal Year: 2010
    ..Our studies will define the therapeutic potential of these cells and help bring novel stem cell therapies to the clinic. ..
  9. Matched and Haploidentical transplantation for Adults with Sickle Cell Anemia
    Neal Flomenberg; Fiscal Year: 2010
    ..We believe we have the appropriate patient population, technology, and health care team in place to substantially improve these issues and help this population of patients. (End of Abstract) ..
  10. Notch Signaling in Alloimmunity
    Ivan Maillard; Fiscal Year: 2013
    ....
  11. Predictive Mathematical Models for Rational Design of Chemoimmunotherapy of Leuke
    Craig A Mullen; Fiscal Year: 2010
    ..This project will develop mathematical techniques that will help doctors combine chemotherapy and immunological therapy in new ways that will keep leukemia from coming back after bone marrow transplantation. ..
  12. OPTIMIZING ALLOGENEIC TRANSPLANTATION USING CXCR4 BLOCKADE
    John F DiPersio; Fiscal Year: 2010
    ..These studies will provide the foundation for generating improved stem cell allografts in less time and with improved safety to the donors and outcomes for the recipients compared to G-CSF. ..
  13. Immune Modulation/Hematopoietic Cell Transplantation
    ROBERT JON SOIFFER; Fiscal Year: 2010
    ....
  14. Development of safe and efficient gene therapy strategies for hemoglobinopathies
    Hans Peter Kiem; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: We propose to develop safer and more clinically applicable gene therapy treatment plans for genetic diseases in blood-forming stem cells, especially for defects in red blood cells which carry oxygen. ..
  15. Neurorestorative therapy of stroke with HUCBC in T2DM rats
    Jieli Chen; Fiscal Year: 2013
    ..This proposal is highly clinically relevant and if successful, will significantly impact the treatment of diabetic and possibly all stroke patients. ..
  16. Autologous Lung Multipotent Stromal Cell Therapy for Emphysema
    Edward P Ingenito; Fiscal Year: 2013
    ..This trial design will allow us to recover the LMSC-treated organ for histological analysis to characterize responses to LMSC treatment at the cellular level. ..
  17. Transplantation of Genetically Modified, Immune-privileged Steroli Cells
    Jannette M Dufour; Fiscal Year: 2012
    ..In the long-term these cells could provide an unlimited supply of genetically modified tissue that could be transplanted without the use of chronic immunosuppression as a means of treatment for multiple disorders. ..
  18. Stem Cell Priming to Enhance Engraftment
    Mary J Laughlin; Fiscal Year: 2010
    ....
  19. WEILL CORNELL PROGRAM OF EXCELLENCE IN GENE THERAPY
    Ronald Crystal; Fiscal Year: 2005
    ..End of Abstract) ..
  20. Enhancing the Safety of Allogeneic Transplantation
    Daniel J Weisdorf; Fiscal Year: 2013
    ..Improving engraftment and post transplant immune recovery may limit these hazards and augment the success of all transplantation. ..
  21. Engraftment and in vivo selection of HIV-protected stem cells
    Ann E Woolfrey; Fiscal Year: 2013
    ....
  22. Regulatory T Cells in Allogeneic Transplantation
    Robert S Negrin; Fiscal Year: 2010
    ..Preliminary studies, so far, have demonstrated favorable results with this specific type of transplant. ..
  23. NK Cells, Their Receptors and Unrelated Donor Transplant
    Jeffrey S Miller; Fiscal Year: 2013
    ..The program also promises to change practice of allogeneic transplantation, to the greater benefit of patients with advanced leukemia. ..
  24. Investigation of the Molecular Basis of T Cell Alloreactivity
    GERALD PATRICK MORRIS; Fiscal Year: 2013
    ..Molecular Definition of the Alloreactive T Cell Receptor Repertoire ..
  25. Blood and Marrow Transplant Clinical Research Network
    Ryotaro Nakamura; Fiscal Year: 2013
    ..This study addresses an important health care issue, particularly for patients entering the seventh decade of life who have no other curative options. ..
  26. Functional Analysis of the Hematopoietic Niche during Ontogeny
    GRACA DUARTE ALMEIDA-PORADA; Fiscal Year: 2012
    ..abstract_text> ..
  27. Impact of Comorbidities on Outcomes of Allogeneic Transplantation
    Mohamed Sorror; Fiscal Year: 2013
    ..abstract_text> ..
  28. Regulatory T Cells in Allogeneic Transplantation
    Robert S Negrin; Fiscal Year: 2013
    ....
  29. Enhancement of Hematopietic Stem Cell Engraftment with CD+ Marrow Progenitors
    Matthew J Schuchert; Fiscal Year: 2013
    ..Such knowledge would afford new hope in thoracic organ transplant recipients and in patients suffering from a wide range of congenital and acquired hematologic disorders...
  30. Minor Histocompatilibity Vaccination After Allo-Transpl*
    Koen Van Besien; Fiscal Year: 2004
    ..Blood, marrow and skin biopsy samples will be obtained for correlative studies relating to immune reconstitution and minimal residual disease and compared with historical controls. ..
  31. MOLECULAR ICE CONTROL FOR ENGINEERED TISSUES
    Michael Taylor; Fiscal Year: 2003
    ..The potential markets are enormous. Cryopreservation methods, which result in retained viability and function, will be licensed to the tissue engineering industry. ..
  32. Identification of Minor Histocompatibility Antigens
    David Miklos; Fiscal Year: 2006
    ..Dr. Miklos' research will be performed in the laboratory of Dr. Jerome Ritz, a leader in the field of immunology and allogeneic HSC transplantation at the Dana-Farber Cancer Institute...
  33. CTLA-4 Blockade in Allo Stem Cell Transplantation
    Edward Ball; Fiscal Year: 2005
    ..abstract_text> ..
  34. HOMOLOGOUS PREPUBERTAL CANINE GONAD TRANSPLANTATION
    JENNIFER PULLIUM; Fiscal Year: 2007
    ..aims include examining the role of dog leukocyte antigen (DLA) haplotype in determining the success of homologous transplantation of prepubertal testes and ovaries when there is at least a partial identity match...
  35. Busulfan conditioning: optimization, kinetics, genomics
    Koen Van Besien; Fiscal Year: 2007
    ..We propose to study expression of GST's in leukemia cells and to correlate GST expression with genotype and with response to transplant. These studies are exploratory. [unreadable] [unreadable]..
  36. Reducing the Pathology of Globoid Cell Leukodystrophy with Stem Cell Therapy
    CYNTHIA BAILLIF RIPOLL; Fiscal Year: 2010
    ..The approach outlined in this study using a mouse model may be applicable to humans suffering from GLD, and would circumvent the problem of GVHD present in current therapies employed to treat this disease. ..
  37. Complement C1q Function in Allogeneic Transplantation
    Kenneth Christopher; Fiscal Year: 2009
    ..The long-term goal is to train a physician-scientist that will succeed in the field of transplantation immunology. ..
  38. MODULATION OF POST BMT LUNG INJURY BY CAPTOPRIL
    Leo Gordon; Fiscal Year: 1999
    ..The results obtained from these studies will provide new information on the mechanisms of IPS after BMT and should have important implications for patient, who undergo BMT. ..
  39. MCC Cord Blood Stem Cell Transplantation Study
    Shelly Carter; Fiscal Year: 2001
    ..The purpose of this program is to accelerate and oversee clinical research in the rapidly emerging use of umbilical cord blood in place of marrow for transplantation. ..
  40. MECHANISMS OF TOTAL LYMPHOID IRRADIATION TOLERANCE
    Elizabeth Field; Fiscal Year: 2001
    ..The results may renew the transplant communitys interest in pursuing TLI as an important adjunct therapy in allogeneic transplantation. ..
  41. TRANSPLANT CENTER FOR UMBILICAL CORD STEM CELL
    Joanne Kurtzberg; Fiscal Year: 2001
    ..The purpose of this program is to accelerate and oversee clinical research in the rapidly emerging use of umbilical cord blood in place of marrow for transplantation. ..
  42. ABO ANTIBODIES--PARADIGM FOR HUMAN REPERTOIRE EVOLUTION
    TYLIS CHANG; Fiscal Year: 2000
    ..Chang will gain the technical and professional expertise to make future contributions to the field of immunohematology as an independent clinical scientist. (End of Abstract) ..
  43. Center for Umbilical Cord Stem Cell Transplan
    Eric Sievers; Fiscal Year: 2000
    ..The purpose of this program is to accelerate and oversee clinical research in the rapidly emerging use of umbilical cord blood in place of marrow for transplantation. ..
  44. Hematopoietic Support by Adipose-Derived Stromal Cells
    Jeffrey Gimble; Fiscal Year: 2001
    ..Each year, 20,000+ patients under this therapy at an individual cost of $100,000. Artecel Sciences technology has the potential to significantly reduce the clinical and financial burden of these procedures...
  45. SYNTHETIC INHIBITORS OF CD8+T CELLS IN TRANSPLANTATION
    Robert Korngold; Fiscal Year: 2004
    ..abstract_text> ..
  46. Centers For Clinical Research on TransplantaTION
    Eva Guinan; Fiscal Year: 2000
    ..The purpose of this program is to accelerate and oversee clinical research in the rapidly emerging use of umbilical cord blood in place of marrow for transplantation. ..
  47. COLLECTION AND STORAGE CENTER FOR CLINICAL RESEARCH
    John Fraser; Fiscal Year: 2000
    ..The purpose of this program is to accelerate and oversee clinical research in the rapidly emerging use of umbilical cord blood in place of marrow for transplantation. ..
  48. Mixed HSC Chimerism in Sensitized Recipients
    SUZANNE ILDSTAD; Fiscal Year: 2005
    ....
  49. Minimal Treatment Models of Stem Cell Engraftment
    Peter Quesenberry; Fiscal Year: 2004
    ..These studies should shed light on the stem cell/accessory cell mechanism involved in both syngeneic and allogeneic transplantation and provide approaches to minimize toxicity in both types of transplantation. ..
  50. Notch Mediated Expansion of Hematopoietic Precursers
    Irwin Bernstein; Fiscal Year: 2007
    ..unreadable] [unreadable] [unreadable]..
  51. SURGICAL STUDIES OF CMV REACTIVATION IN TRANSPLANTATION
    Michael Abecassis; Fiscal Year: 2003
    ....
  52. USE OF ADIPOSE-DERIVED PREADIPOCYTES IN BONE DISOREDERS
    Jeffrey Gimble; Fiscal Year: 2002
    ..This has commercial application to orthopedic and periodontal surgical treatments of joint replacement, fracture repair, and bone resorption secondary to tooth decay...
  53. TRANSPLANTATION OF ALLOGENEIC MESENCHYMAL STEM CELLS
    Omer Koc; Fiscal Year: 2000
    ..This project will allow him to learn transplantation biology of hMSCs in humans and expand its therapeutic development into allogeneic setting. ..
  54. CELLS FOR PROTECTION OF IMPLANTED B ISLETS
    Deborah Hall; Fiscal Year: 2000
    ..The market for such implants could be $1 billion a year in the U.S. alone. ..
  55. In Vivo Stem Cell Selection in Neonatal Allo-Transplants
    Karin Gaensler; Fiscal Year: 2006
    ..This negative selection strategy may also abrogate autonomous clonal proliferation of transduced donor cells after forced enrichment and expansion in vivo, an important potential safety issue. ..
  56. Stem Cell Differentiation: Long Term Follow Up
    Beverly Torok Storb; Fiscal Year: 2004
    ..The information gained should help define whether, and under what circumstances, marrow derived stem cells contribute to other tissues following allogeneic transplantation. ..
  57. Cord Blood Transplantation
    Nelson Chao; Fiscal Year: 2005
    ..abstract_text> ..
  58. Hematopoietic cell Transplants for Autoimmune Diseases
    Judith Shizuru; Fiscal Year: 2005
    ..A further goal of this application is to understand the mechanism(s) by which the proposed autologous and allogeneic HCT regimens alter immune responses to autoantigens. ..
  59. BIOLOGIC & CLINICAL PROPERTIES OF CD4 STRUCTURAL ANALOGS
    Neal Flomenberg; Fiscal Year: 2001
    ..The composite information gained should allow assessment of the efficacy of the present generation of CD4 analogs as well as the design and preclinical testing of next generation products. ..